Merck said it expects its 2022 sales to increase as much as 18% over last year, mostly on sales of its new COVID-19 pill, molnupiravir.
You're not a member! Trial today
Posted on | by Leon Hinde
Level 29 Chifley Tower
2 Chifley Square
Sydney, NSW 2000
1300 614 002
Investor Signals Pty Ltd
ABN 44 143 555 453
Send our ASX Research to your Inbox
Or start a free thirty day trial for our full service, which includes our ASX Research.